Navin Fluorine International Ltd Q4 FY25 Earnings Analysis

- **Strong growth visibility for FY '26:** Particularly in CDMO and Specialty Chemicals driven by ongoing projects and order pipeline. - **Project Nectar:** Focus on dedicated capacity ramp-up in the first year; open capacity qualification and additional molecule development expected to drive growth in the second year. - **Agro Specialty Plant at Dahej:** Commercial dispatches started; peak revenue expected around FY '27 with gradual ramp-up. - **R32 Capacity Expansion:** Additional 4,500 MT capacity commissioning by Feb 2025; discussions for further expansion ongoing, with increased demand expected domestically and globally. - **CDMO Business:** Constructive outlook with multiple molecules under development; targeting over $100 million revenue by FY '27, with ~30% from Fermion contract. - **AHF Capacity Utilization:** Expected to grow over the next 4-5 years with focus on higher realization per kg and new value-chain entry.

- Company aims to achieve a sustainable EBITDA margin near 25% by FY '25 end, up from 15% previously. - Operating EBITDA grew 95% YoY in Q3 FY '25, with margins improving from 15.13% to 24.3%. - Revenue growth driven across all segments: HPP, Specialty Chemicals, and CDMO. - Specialty Chemicals expected to ramp up with new capacity; peak revenue for major projects anticipated by FY '26-FY '27. - CDMO segment expected to exceed $100 million scale with new orders and cGMP4 project commissioning by Q3 FY '26. - New agro specialty plant at Dahej commercialized, contributing to revenue growth. - Employee costs expected to stabilize or decrease slightly, improving cost efficiency. - Tight financial framework and disciplined project execution aim to sustain growth and robust cash flows. - Overall outlook is positive, with strong order book and operational efficiencies underpinning future earnings growth.

- INR540 crores capex: Specialty Chemicals project with expected peak annual revenue around INR515 crores, achieving peak in 2 years from commissioning (FY '27). - INR235 crores capex: R32 expansion project underway, discussions ongoing with global majors; potential announcements expected in the first half of FY '26. - INR125 crores capex: Part of ongoing CDMO/cGMP projects. - INR160 crores Phase 1 capex: cGMP4 plant expected to come online in November, with planned accelerated Phase 2 expansion using common infrastructure. - INR30 crores capex: Surat project with asset turn of ~1.2, starting FY '26 with peak in FY '27. - Focus on ramping Project Nectar, related to agrochemicals, with dedicated and open capacity phases spanning 2 years. - Strategic focus on brownfield expansions and capacity expansions balanced with disciplined project execution to maximize shareholder value.

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company reported a net debt to equity ratio of 0.41 as of December 31, 2024, indicating manageable leverage. - Capex projects are being funded and progressing as planned, with discussions ongoing for potential expansions (e.g., R32 capacity), but no specific details on external fundraising were disclosed. - Management indicated that upcoming capex and growth projects will be driven through internal cash flows and existing resources. - Any announcements regarding new funding or major expansions are anticipated to be communicated in due course, especially possibly during the first half of FY '26. - Overall, no immediate plans for debt or equity raising were disclosed during this call.

- The CDMO business has a strong order book and visibility for FY '26 and beyond, with orders already secured for calendar year (CY) 2025. - A major European customer has placed an order with supply scheduled for FY '26. - U.S.-based major customers have given scale-up orders planned for Q4 FY '25. - The Fermion contract is expected to contribute about 30% towards the $100 million CDMO target by FY '27. - For MPP and dedicated multipurpose plants, the order book visibility is close to peak annual revenue levels for FY '26, with ongoing efforts to secure higher volumes. - Specialty Chemicals sees steady growth with increased inquiries and new molecule developments under progress. - Project Nectar has started dispatches, focusing initially on dedicated capacity, with qualification campaigns and open capacity orders expected to ramp over two years.